Skip to content

Baxter International BAX Impairment Charges

Impairment Charges at other companies

Medline, Inc.
 logo
Medline, Inc. MDLN
$0
Medtronic logo
MedtronicMDT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Segments

By segment

See full
Healthcare Systems & Technologies$290M

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetImpairmentCharges.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's impairment charges?
Baxter International (BAX) reported impairment charges of $0 in Q1 2026.
How has Baxter International's impairment charges changed year-over-year?
Baxter International's impairment charges decreased by 100.0% year-over-year, from $22M to $0.
What does impairment charges mean?
A write-down in the value of assets that are no longer expected to generate their original projected returns.
How do you interpret impairment charges?
High impairment charges signal poor past capital allocation or deteriorating market conditions for specific product lines.
How does impairment charges compare across companies?
Often seen in companies undergoing portfolio transformation or those facing competitive disruption in specific product segments.